Literature DB >> 33829416

Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis.

Yue Zhou1,2,3, Xin Yang4,5, Huipan Liu1,2,3, Wenbin Luo6, Hanxiang Liu1,2,3, Taiyong Lv1,2,3, Junzheng Wang1,2,3, Jianhua Qin4,5, Santao Ou4,5, Yue Chen7,8,9.   

Abstract

PURPOSE: Renal fibrosis is a pathological state in the progression of chronic kidney disease. Early detection and treatment are vital to prolonging patient survival. Renal puncture examination is the gold standard for renal fibrosis, but it has several limitations. This study aims to evaluate the diagnostic performance of a novel PET radiotracer, [68Ga]Ga-fibroblast activation protein inhibitor (FAPI)-04, which specifically images fibroblast activation protein (FAP) expression for renal fibrosis.
METHODS: All patients underwent renal puncture before receiving [68Ga]Ga-FAPI-04 PET/CT imaging. They then underwent [68Ga]Ga-FAPI-04 PET/CT and immunochemistry examinations. The data obtained were analyzed.
RESULTS: The [68Ga]Ga-FAPI-04 PET/CT examination results demonstrated that almost all patients (12/13) exhibited increased radiotracer uptake. The maximum standardized uptake value (SUVmax) in patients with mild, moderate, and severe fibrosis was 3.92 ± 1.50, 5.98 ± 1.6, and 7.67 ± 2.23, respectively.
CONCLUSION: Compared with renal puncture examination, non-invasive imaging of FAP expression through [68Ga]Ga-FAPI-04 PET/CT quickly demonstrates bilateral kidney conditions with high sensitivity. [68Ga]Ga-FAPI-04 PET/CT can facilitate the evaluation of disease progression, diagnosis, and the development of a treatment plan.

Entities:  

Keywords:  PET/CT; Renal fibrosis; Renal puncture; [68Ga]Ga-FAPI

Year:  2021        PMID: 33829416     DOI: 10.1007/s00259-021-05343-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

1.  Prevalence of chronic kidney disease in China: a cross-sectional survey.

Authors:  Luxia Zhang; Fang Wang; Li Wang; Wenke Wang; Bicheng Liu; Jian Liu; Menghua Chen; Qiang He; Yunhua Liao; Xueqing Yu; Nan Chen; Jian-e Zhang; Zhao Hu; Fuyou Liu; Daqing Hong; Lijie Ma; Hong Liu; Xiaoling Zhou; Jianghua Chen; Ling Pan; Wei Chen; Weiming Wang; Xiaomei Li; Haiyan Wang
Journal:  Lancet       Date:  2012-03-03       Impact factor: 79.321

Review 2.  Autophagy in kidney homeostasis and disease.

Authors:  Chengyuan Tang; Man J Livingston; Zhiwen Liu; Zheng Dong
Journal:  Nat Rev Nephrol       Date:  2020-07-23       Impact factor: 28.314

Review 3.  Macrophages: versatile players in renal inflammation and fibrosis.

Authors:  Patrick Ming-Kuen Tang; David J Nikolic-Paterson; Hui-Yao Lan
Journal:  Nat Rev Nephrol       Date:  2019-01-28       Impact factor: 28.314

Review 4.  Myofibroblast in Kidney Fibrosis: Origin, Activation, and Regulation.

Authors:  Qian Yuan; Roderick J Tan; Youhua Liu
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

5.  Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis.

Authors:  Pinak S Acharya; Alicia Zukas; Vishal Chandan; Anna-Luise A Katzenstein; Ellen Puré
Journal:  Hum Pathol       Date:  2006-03       Impact factor: 3.466

6.  Dickkopf-3 in aberrant endothelial secretome triggers renal fibroblast activation and endothelial-mesenchymal transition.

Authors:  Mark Lipphardt; Hassan Dihazi; Noo Li Jeon; Sina Dadafarin; Brian B Ratliff; David W Rowe; Gerhard A Müller; Michael S Goligorsky
Journal:  Nephrol Dial Transplant       Date:  2019-01-01       Impact factor: 5.992

Review 7.  Targeting the progression of chronic kidney disease.

Authors:  Marta Ruiz-Ortega; Sandra Rayego-Mateos; Santiago Lamas; Alberto Ortiz; Raul R Rodrigues-Diez
Journal:  Nat Rev Nephrol       Date:  2020-02-14       Impact factor: 28.314

Review 8.  Pathology and natural history of organ fibrosis.

Authors:  Joaquim Majo; Barbara Mara Klinkhammer; Peter Boor; Dina Tiniakos
Journal:  Curr Opin Pharmacol       Date:  2019-10-28       Impact factor: 5.547

9.  Clinicopathological characteristics and predictors of poor outcome in anti-glomerular basement membrane disease - a fifteen year single center experience.

Authors:  Zafirah Zahir; Asif Sadiq Wani; Narayan Prasad; Manoj Jain
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

View more
  6 in total

1.  Bartter syndrome with multiple renal and liver cysts: a case report.

Authors:  Yemei He; Yue Zhou; Weihua Wu; Yue Chen; Santao Ou
Journal:  Int Urol Nephrol       Date:  2022-06-29       Impact factor: 2.370

2.  Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG Uptake in Esophageal Cancer.

Authors:  Huipan Liu; Zhi Hu; Xiao Yang; Tianyang Dai; Yue Chen
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

Review 3.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

4.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161

5.  [68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease.

Authors:  Patrick Conen; Francesca Pennetta; Katharina Dendl; Fabian Hertel; Andreas Vogg; Uwe Haberkorn; Frederik L Giesel; Felix M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-06       Impact factor: 10.057

Review 6.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

Authors:  Tianshuo Yang; Long Ma; Haodong Hou; Feng Gao; Weijing Tao
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.